Y-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on Friday

Y-mAbs Therapeutics (NASDAQ:YMAB) is scheduled to be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter last year, the business earned ($0.14) earnings per share. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Up 1.5 %

Shares of Y-mAbs Therapeutics stock opened at $15.10 on Wednesday. Y-mAbs Therapeutics has a one year low of $4.69 and a one year high of $20.90. The stock’s fifty day moving average is $14.05 and its 200 day moving average is $13.14.

Insider Transactions at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 100,000 shares of company stock valued at $1,338,100. 22.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Finally, BMO Capital Markets decreased their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.14.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.